Literature DB >> 6853834

Stevens-Johnson syndrome managed in the Clinitron bed.

P Davies, D W Ryan.   

Abstract

Entities:  

Mesh：

Year:  1983        PMID： 6853834     DOI： 10.1007/bf01699263

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN： 0342-4642            Impact factor:   17.440


× No keyword cloud information.
  5 in total

1.  Ocular manifestations of toxic epidermal necrolysis associated with allopurinol use.

Authors:  T O Bennett; J Sugar; S Sahgal
Journal:  Arch Ophthalmol       Date:  1977-08

2.  Fluidised-bead bed in the intensive-therapy unit.

Authors:  C W Thomson; D W Ryan; L J Dunkin; M Smith; M Marshall
Journal:  Lancet       Date:  1980-03-15       Impact factor: 79.321

3.  Intensive therapy unit management of toxic epidermal necrolysis: practical aspects.

Authors:  A Y Finlay; J Richards; P J Holt
Journal:  Clin Exp Dermatol       Date:  1982-01       Impact factor: 3.470

4.  Toxic epidermal necrolysis.

Authors:  J Rasmussen
Journal:  Med Clin North Am       Date:  1980-09       Impact factor: 5.456

5.  The effect of environmental temperature on the metabolism and nutrition of burned patients.

Authors:  J W Davies; S O Liljedahl
Journal:  Proc Nutr Soc       Date:  1971-09       Impact factor: 6.297
  5 in total
  3 in total

1.  The influence of environmental temperature (32 degrees C) on catabolism using the Clinitron fluidised bed.

Authors:  D W Ryan
Journal:  Intensive Care Med       Date:  1983       Impact factor: 17.440

Review 2.  Clinical features and management of severe dermatological reactions to drugs.

Authors:  M C Raviglione; A Pablos-Mendez; R Battan
Journal:  Drug Saf       Date:  1990 Jan-Feb       Impact factor: 5.606

Review 3.  Allopurinol hypersensitivity: a systematic review of all published cases, 1950-2012.

Authors:  Sheena N Ramasamy; Cameron S Korb-Wells; Diluk R W Kannangara; Myles W H Smith; Nan Wang; Darren M Roberts; Garry G Graham; Kenneth M Williams; Richard O Day
Journal:  Drug Saf       Date:  2013-10       Impact factor: 5.228
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.